The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Revalesio’s experimental therapy RNS60 for people diagnosed with amyotrophic lateral sclerosis (ALS). A phase 2 trial is now recruiting participants. Fast Track designation is intended to shorten the time it takes for the…
Treatment with EHP-102, an investigational cannabinoid-derived medicine, reduced weight loss, preserved motor neurons of the spinal cord, and lowered the abnormal reactivity of astroglial cells in a mouse model of amyotrophic lateral sclerosis (ALS), new research shows. Findings were recently published in the study, “Neuroprotective effects of…
Cytokinetics has awarded the ALS Association Golden West Chapter with its first communications fellowship, part of a company initiative directed at nonprofit organizations to increase public education and awareness of their programs and care services, as well as to elevate patients’ voices. “As a longstanding partner…
BrainStorm Cell Therapeutics has partnered with the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute for the manufacturing of NurOwn, a therapy candidate for amyotrophic lateral sclerosis (ALS), for BrainStorm’s ongoing Phase 3 trial. This is the second U.S. production site…
Skyhawk Therapeutics and Celgene have agreed to collaborate for five years to discover, develop, and commercialize innovative small molecule treatment options for neurological diseases with high unmet medical needs, including amyotrophic lateral sclerosis (ALS) and Huntington’s disease. Several genetic disorders are caused by “exon skipping,” which means…
The brain’s smallest blood vessels stimulate the growth of spinal cord nerve cells at an early stage of their development, researchers at Southern California’s Cedars-Sinai group report. Their discovery, made with a tiny biological chip, could help shed light on the causes of amyotrophic lateral sclerosis (ALS). The article they wrote…
The more a person is exposed to diesel exhaust, the greater the chance they will develop ALS, a Harvard University study on Denmark reports. The team will present the findings at the American Academy of Neurology‘s 70th Annual Meeting in Los Angeles, April 21 to 27. The presentation is titled “…
Increasing the levels of a neurotransmitter-generating brain enzyme that is in short supply in paralysis disorders restored movement in a fly model of ALS, an Italian study shows. Bolstering the Gad1 enzyme’s levels also led to the return of a pre-disease pattern of nerve cell organization, the researchers said. The…
Researchers at Sweden’s University of Gothenburg say low red blood cell count at a young age is a risk factor for amyotrophic lateral sclerosis (ALS). Disease onset was also associated with low muscle strength and low body fat during the later teen years. ”One should never overstate conclusions from a…
Scientists at the University of Edinburgh discovered that the human neuromuscular junction (NMJ) — a cell connection between neurons and muscle that enables motion — is different in size and structure than other mammals, including mice, which are routinely used in research. “Our findings provide unique insights into the…
Get regular updates to your inbox.